Research Options:

Week of Expected Pricing 10/11/2021
Company Name PYXIS ONCOLOGY INC
Proposed Ticker PYXS
CUSIP 747324101
Business Description A preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. We develop our product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Lead Underwriter BofA Securities, Inc, Credit Suisse Securities (USA) LLC, Jefferies LLC, William Blair & Company, L.L.C.
Co-Managers LifeSci Capital, LLC
Initial Shares 83,40,000
Revised Initial Shares 1,05,00,000
Initial Price $14.00-$16.00
Revised Price N/A
Final Price $16.00
Final Ticker PYXS

 

 

   
  © 2024 ICE Data Services. All rights reserved.